

04.04.2024

**Subject: Mandatory Dispensing Procedure for TGA approved Cholestyramine for Oral Suspension, USP Light Powder 4g Pouch (Ascend, USA)**

Dear Pharmacist,


This is to inform you about the specific dispensing requirements mandated by the Therapeutic Goods Administration (TGA) under Section 19A for Cholestyramine for oral suspension, USP light powder 4g pouch, manufactured by Ascend, USA.

To ensure compliance with the TGA's regulations, it is imperative that each pouch of Cholestyramine is dispensed to patients in a clear zip-lock bag. This packaging must also include the USA Patient Information Leaflet (PIL), the Dear Healthcare Provider Letter (DHCPL), and the Direct Patient Letter (DPL) with the **red text box** present in letters being clearly visible through the bag.

**Please note: CONTAINS MANNITOL, FRUCTOSE, SORBITOL, ASPARTAME**

Prior to taking this product, please check with your healthcare professional to determine if these inactive ingredients are suitable for you.

**Prior to dispensing, please print the PIL, DHCPL and DPL through this QR code (in case it is not a part of packaging).  
NOTE: The printed documents to be included in a zip-lock bag with the RED TEXT BOX clearly visible through the bag**



To facilitate this process, we have provided a **QR code** that allows you and your staff to access and print the necessary documents (PIL, DHCPL, and DPL). It is essential that these documents are included with each dispensed product to meet the TGA's regulatory requirements and to provide patients with the necessary information about their medication. Please ensure that your team is informed about this mandatory dispensing procedure and that they adhere to it strictly to avoid any regulatory issues. Compliance with these guidelines is essential for the continued availability of this product under Section 19A approval.

We appreciate your cooperation and commitment to maintaining the highest standards of patient care. Thank you for your attention to this important matter.

For further information, please contact Pharmacor Pty Ltd on 1800 138 805 / 0469620006 or email [sajjad@pharmacor.com.au](mailto:sajjad@pharmacor.com.au)

Sincerely,

Pharmacor Pty Limited